日本の陽子線治療市場：製品タイプ別、適応症別、設定タイプ別、エンドユーザー別、地域別、機会、予測、2018年～2032年

日本の陽子線治療の市場規模は、2025年から2032年にかけて8.20％のCAGRで拡大し、2024年の8,116万米ドルから2032年には1億5,247万米ドルになると予測されます。日本の陽子線治療市場は、健康への支出の増加、医師の高度治療志向の高まり、がん罹患率の上昇など、いくつかの要因の影響を受けています。日本は陽子線治療施設の数で世界有数の国であり、最先端の放射線治療技術の増加と継続的な技術進歩が市場をさらに牽引しています。ヘルスケア専門家および国民全体における先進的がん治療に対する意識の高まりも、この市場の主要な促進要因です。

日本のがん罹患率は着実に上昇しており、その結果、先進治療のニーズがますます高まっています。国立がん研究センターと国立研究開発法人国立がん研究開発機構は、2024年の日本のがん罹患数は97万9,300人になると予測しており、これは懸念材料を反映しています。この課題に対処するため、日本は医療技術の最前線に立ち、陽子線治療のような新しい治療を発見してきました。この高度に的を絞った治療法は、周囲の健康な組織を温存しながら腫瘍を治療するように設計されているため、望ましい選択肢となっています。すでに多くの専門施設がこの技術を導入しているが、がんの負担増は陽子線治療の需要をさらに高めています。

日本は、最先端のがん医療をより多くの国民が受けられるよう努力してきました。日本の国民皆保険制度は、患者の自己負担を低く抑え、包括的な医療を利用できるようにしています。2024年6月、日本の厚生労働省は早期の肺がん陽子線治療を国民健康保険でカバーすると発表し、大きな話題となっています。この画期的な動きは、多くの人にとって治癒のための選択肢を後押しするものです。患者が先進的な陽子線治療を利用できるようになると同時に、がんとの闘いにおける技術革新と公平性への日本の献身を確固たるものにするものです。

当レポートでは、日本の陽子線治療市場について調査し、市場の概要とともに、製品タイプ別、適応症別、設定タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 日本の陽子線治療市場の見通し、2018年～2032年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2024年
  • 製品タイプ別
  • 適応症別
  • 設定タイプ別
  • エンドユーザー別
  • 地域別

第5章 需要供給分析

第6章 輸出入の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ5の情勢
  • Hitachi High-Tech Corporation
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.
  • Toshiba Energy Systems & Solutions Corporation
  • Ion Beam Applications SA (IBA)
  • Elekta Co., Ltd
  • Mitsubishi Electric Corporation
  • Mevion Medical Systems, Inc.
  • B dot Medical Inc.
  • ProTom International

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Proton Therapy Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan Proton Therapy Market, By Volume, In Million Units, FY2018-FY2032F
• Figure 3. Japan Proton Therapy Market Share (%), By Product Type, FY2018-FY2032F
• Figure 4. Japan Proton Therapy Market Share (%), By Indications, FY2018-FY2032F
• Figure 5. Japan Proton Therapy Market Share (%), By Setup Type, FY2018-FY2032F
• Figure 6. Japan Proton Therapy Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan Proton Therapy Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Product Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Indications Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Setup Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024

Japan proton therapy market is predicted to grow at a CAGR of 8.20% between FY2025 to FY2032, rising from USD 81.16 million in FY2024 to USD 152.47 million by FY2032. The proton therapy market in Japan is influenced by several factors, including rising expenditure on health, a growing trend toward advanced treatment among physicians, and a growing incidence of cancer. Japan is among the world's leading countries in the number of proton therapy facilities, with increased state-of-the-art radiotherapy technology and continued technological advancements further driving the market. Increased awareness among healthcare professionals and the population as a whole of advanced cancer treatment is also a key driver for this market.

The cancer incidence in Japan has been rising steadily, which has resulted in an ever-growing need for advanced treatment. The National Cancer Center and National Research and Development Agency of Japan projected that, in 2024, there were 979,300 cancer incidences in the country, reflecting a cause for concern. To address this challenge, Japan has been at the forefront of medical technology, having discovered new treatments like proton therapy. This highly targeted intervention is designed to treat tumors while sparing surrounding healthy tissues, thus making it a preferred choice. With many specialized centers already having this technology, the increasing burden of cancer is further fueling the demand for proton therapy, which provides better treatment outcomes and is a demonstration of Japan's leadership in sophisticated cancer treatment.

Japan has been striving to make cutting-edge cancer care more available to the public. Japan's universal public health insurance ensures that a comprehensive range of medical care is made accessible, keeping patients' out-of-pocket expenses low. In June 2024, Japan's Ministry of Health, Labour, and Welfare made headlines by announcing that early lung cancer proton therapy would be covered by national health insurance. This groundbreaking move encourages a curative option for many. It enables patients to take advantage of advanced proton therapy while cementing Japan's dedication to innovation and equity in the fight against cancer.

Advancements in Cancer Treatment Impacting Japan Proton Therapy Market

Japan is at the forefront of creating novel cancer treatments by utilizing cutting-edge technologies including immunotherapy, AI-powered diagnostics, and personalized medicine. Proton therapy is one of the remarkable advancements, giving precise radiation with less harm to the surrounding healthy tissues, and best suited for pediatric and persistent cancers. Japan has made substantial investments in the expansion of several proton therapy centers, owing to an increase in cancer incidence and government support. Some of the innovations in cancer treatment, such as flash therapy and miniaturized proton systems, are reducing its cost and increasing its efficiency. Several companies have collaborated with universities to innovate and improve cancer care innovations. Sumitomo Heavy Industries Ltd. and Fujita Health University collaborated and initiated research for a new BNCT and an extremely powerful new cancer drug in December 2024. These developments can cure presently incurable cancers such as pancreatic cancer. This technology is changing the way treatments are done in cancer and presenting huge market expansion opportunities for proton treatment in Japan, making it a pioneer for cancer treatment breakthroughs. This partnership creates new opportunities for growth and innovation in the sector. These advancements, coupled with the growing need for minimally invasive treatments, are fueling the expansion of Japan's proton therapy market, drawing domestic and foreign investments. Through additional research, Japan will be able to position itself at the forefront of future cancer therapies and take its rightful position in oncology treatment innovations globally.

Higher Adoption Supports Market Expansion

Japan is accelerating the adoption of advanced therapies owing to increased investments in its healthcare facilities. This new paradigm presents promising opportunities for proton therapy in Japan, with advanced treatments increasingly used in the clinic. With rising adoption in government and private cancer institutes, proton therapy is gaining traction in the Japanese cancer treatment industry. Chubu International Medical Center launched its "Proton Beam Therapy Department" in March 2024 as a pioneer in cancer treatment. The center, being Japan's first to use Varian's newest "ProBeam" technology, will subsequently introduce Boron Neutron Capture Therapy (BNCT). The technology is backing the growing demand for proton therapy in Japan, propelling the market's growth and calling for continuous innovations to meet the evolving requirements of medical professionals. Studies are ongoing to improve its use, pushing its application into paediatrics, head and neck, and other recurrent cancers. While the need for targeted and minimally invasive treatments increases, Japan is becoming the world leader in proton therapy technology, which is defining the future of cancer care.

Hospitals are the Major End-users of the Proton Therapy in Japan

Hospitals are the most crucial players in the Japanese proton therapy market, and they are the major end-users of this novel cancer treatment. Large hospitals have been the forerunners in adopting this technology in their cancer departments because proton therapy centers cost a lot of money to establish. They also facilitate research and innovation. For instance, in January 2025, the Tokyo Metropolitan Hospital Organization invested USD 121 million (5 billion yen) in establishing a proton beam therapy center at Komagome Hospital in Tokyo, Japan. The center will begin treating patients in fiscal 2030. This indicates that Japanese hospitals are significant consumers of this innovative treatment. The rising incidence of cancer, along with government encouragement of new treatment, has also strengthened their position. Moreover, partnering with research centers facilitates the development of new technologies and makes treatment easily available to patients. With more emphasis on precision medicine, hospitals continue to expand their proton therapy services, making them significant contributors to market growth and development.

Future Market Scenario (FY2025 -FY2032F)

Japan's proton therapy market will grow strongly with enhanced precision oncology, rising cancer cases, and strong government backing. Rising investments in new radiation technology and expanding healthcare infrastructure further augment growth. The high cost of treatment and restricted reimbursement, however, remains a challenge. Nevertheless, the market is projected to thrive with enhanced awareness and accessibility, further solidifying Japan in advanced cancer therapy.

In June 2023, B dot Medical Inc. formed a strategic partnership with RaySearch Laboratories AB to advance proton therapy by integrating RayStation and RayCare with B dot Medical's ultra-compact proton therapy system. The collaboration intends to make proton therapy more accessible to healthcare professionals to treat more patients. This partnership fosters market expansion and encourages widespread adoption of proton therapy by maximizing system capabilities and providing advanced solutions. Furthermore, it contributes to advancing radiation oncology and achieving the mission of 'proton for everyone'.

Key Players Landscape and Outlook

Japan's proton therapy market players follow various strategies to strengthen their market reach. They focus on getting regulatory approvals to facilitate ease of product entry and compliance. Strategic partnerships with medical institutions and technology companies accelerate innovation and access. Increasing treatment centers, maximizing patient financing options, and research expenditures further deepen their hold. All these strategies together encourage greater adoption and long-term growth in Japan's proton therapy market.

In November 2023, B dot Medical Inc. got approval from the Ministry of Health, Labour and Welfare of Japan for their ultra-compact proton therapy system Phemto, as per the Pharmaceuticals and Medical Devices Act. Phemto is an innovative device, which has a vision of being as tiny as X-ray (LINAC) therapy systems. This clearance reinforces B dot Medical's market position, reflecting its innovation and dedication to making advanced proton therapy easily available to healthcare facilities. Their achievement is evidence of their dedication to revolutionizing radiation oncology.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Proton Therapy Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Systems
      • 4.2.1.1.1. Cyclotron
      • 4.2.1.1.2. Synchrotron
      • 4.2.1.1.3. Synchrocyclotron
    • 4.2.1.2. Services
  • 4.2.2. By Indications
    • 4.2.2.1. Head and Neck Cancer
    • 4.2.2.2. Central Nervous System Cancer
    • 4.2.2.3. Prostate Cancer
    • 4.2.2.4. Breast Cancer
    • 4.2.2.5. Lung Cancer
    • 4.2.2.6. Pediatric Cancer
    • 4.2.2.7. Gastrointestinal Cancer
    • 4.2.2.8. Others
  • 4.2.3. By Setup Type
    • 4.2.3.1. Single-Room Systems
    • 4.2.3.2. Multi-Room Systems
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Proton Therapy Centers
    • 4.2.4.3. Cancer Centers or Institutes
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Product Type
  • 4.3.2. By Indications
  • 4.3.3. By Setup Type
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Developments and Innovations

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 5 Market Players
  • 16.3.1. Hitachi High-Tech Corporation
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Sumitomo Heavy Industries, Ltd.
  • 16.3.3. Varian Medical Systems, Inc.
  • 16.3.4. Toshiba Energy Systems & Solutions Corporation
  • 16.3.5. Ion Beam Applications SA (IBA)
  • 16.3.6. Elekta Co., Ltd
  • 16.3.7. Mitsubishi Electric Corporation
  • 16.3.8. Mevion Medical Systems, Inc.
  • 16.3.9. B dot Medical Inc.
  • 16.3.10. ProTom International

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer